Emerging Growth Research Reiterates Buy on SBC Medical Group Holdings With $9 Price Target

Reuters

Dec 02, 2025

Emerging Growth Research Reiterates Buy on SBC Medical Group Holdings With $9 Price Target

Emerging Growth Research has reiterated its Buy-Extended rating on SBC Medical Group Holdings Inc. $(SBC)$, maintaining a 12-month price target of $9.00 following the company's Q3:25 results. The research highlights SBC's stable revenue and operating profit in the quarter, a robust cash position of $127 million, and minimal long-term debt. The report points to anticipated revenue growth resuming in 2026, supported by domestic expansion and strategic M&A activities. SBC's franchise-based model delivers strong gross margins and cash conversion, positioning the company for long-term growth in the global cosmetic treatment industry.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SBC Medical Group Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 276500) on December 01, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2588770596"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2588770596\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2588770596?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 03:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588770596","market":"us","top_or_hot":-1,"title":"Emerging Growth Research Reiterates Buy on SBC Medical Group Holdings With $9 Price Target","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Emerging Growth Research Reiterates Buy on SBC Medical Group Holdings With $9 Price Target\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Emerging Growth Research has reiterated its Buy-Extended rating on SBC Medical Group Holdings Inc. <a href=\"https://laohu8.com/S/SBC\">$(SBC)$</a>, maintaining a 12-month price target of $9.00 following the company's Q3:25 results. The research highlights SBC's stable revenue and operating profit in the quarter, a robust cash position of $127 million, and minimal long-term debt. The report points to anticipated revenue growth resuming in 2026, supported by domestic expansion and strategic M&amp;A activities. SBC's franchise-based model delivers strong gross margins and cash conversion, positioning the company for long-term growth in the global cosmetic treatment industry.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SBC Medical Group Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 276500) on December 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Emerging Growth Research Reiterates Buy on SBC Medical Group Holdings With $9 Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEmerging Growth Research Reiterates Buy on SBC Medical Group Holdings With $9 Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-02 03:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Emerging Growth Research Reiterates Buy on SBC Medical Group Holdings With $9 Price Target\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Emerging Growth Research has reiterated its Buy-Extended rating on SBC Medical Group Holdings Inc. <a href=\"https://laohu8.com/S/SBC\">$(SBC)$</a>, maintaining a 12-month price target of $9.00 following the company's Q3:25 results. The research highlights SBC's stable revenue and operating profit in the quarter, a robust cash position of $127 million, and minimal long-term debt. The report points to anticipated revenue growth resuming in 2026, supported by domestic expansion and strategic M&amp;A activities. SBC's franchise-based model delivers strong gross margins and cash conversion, positioning the company for long-term growth in the global cosmetic treatment industry.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SBC Medical Group Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 276500) on December 01, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SBC","symbol_name":"SBC Medical Group Holdings Incorporated","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL9lZTzn:1","article_id":"2588770596","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2588770596","pubTimestamp":1764617766,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Emerging Growth Research has reiterated its Buy-Extended rating on SBC Medical Group Holdings Inc. , maintaining a 12-month price target of $9.00 following the company's Q3:25 results. The research highlights SBC's stable revenue and operating profit in the quarter, a robust cash position of $127 million, and minimal long-term debt. The report points to anticipated revenue growth resuming in 2026, supported by domestic expansion and strategic M&A activities. SBC's franchise-based model delivers strong gross margins and cash conversion, positioning the company for long-term growth in the global cosmetic treatment industry.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SBC Medical Group Holdings Inc. published the original content used ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SBC":"SBC Medical Group Holdings Incorporated","BK4196":"保健护理服务"},"translate_title":"新兴增长研究重申买入SBC Medical Group Holdings，目标价为9美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SBC":0.9},"content_text":"Emerging Growth Research Reiterates Buy on SBC Medical Group Holdings With $9 Price Target\n    \n\n        Emerging Growth Research has reiterated its Buy-Extended rating on SBC Medical Group Holdings Inc. $(SBC)$, maintaining a 12-month price target of $9.00 following the company's Q3:25 results. The research highlights SBC's stable revenue and operating profit in the quarter, a robust cash position of $127 million, and minimal long-term debt. The report points to anticipated revenue growth resuming in 2026, supported by domestic expansion and strategic M&A activities. SBC's franchise-based model delivers strong gross margins and cash conversion, positioning the company for long-term growth in the global cosmetic treatment industry.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SBC Medical Group Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 276500) on December 01, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}